Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Rigosertib is a novel small molecule inhibitor targeting Polo-like kinase 1 (PLK1) and phosphoinositide 3-kinase (PI3K).
• Dual inhibition by Rigosertib shows promise in preclinical models for counteracting diverse tumor types.
• Understanding differential cellular responses to Rigosertib is crucial for its therapeutic development.

Purpose of the Study:

• To evaluate the in vitro efficacy of Rigosertib across five distinct human tumor cell lines.
• To investigate the correlation between Rigosertib's efficacy and p53 expression levels.
• To assess Rigosertib's impact on cell cycle progression and related proteins.

Main Methods:

• In vitro treatment of A549 (lung adenocarcinoma), MCF-7, MDA-MB231 (breast cancer), RPMI 8226 (multiple myeloma), and U87-MG (glioblastoma) cell lines with Rigosertib.
• Dose- and time-response assessments of Rigosertib's cytotoxic effects.
• Analysis of p53 expression levels and cell cycle alterations in response to treatment.

Main Results:

• Rigosertib demonstrated dose- and time-dependent efficacy across all tested cell lines.
• A549 lung adenocarcinoma cells exhibited the highest sensitivity to Rigosertib, while U87-MG glioblastoma cells were the most resistant.
• Highest p53 levels were observed in A549 cells, with the lowest in U87-MG cells, correlating with sensitivity.
• Cell cycle alterations occurred at lower Rigosertib concentrations in A549 cells compared to U87-MG cells.

Conclusions:

• Rigosertib exhibits variable efficacy against different human tumor cell lines.
• Cellular sensitivity to Rigosertib correlates with p53 expression levels and cell cycle modulation.
• Rigosertib presents potential as an antineoplastic agent, particularly for human lung cancer.